EXAS's OncoType DX demonstrates the omission of chemotherapy in postmenopausal breast cancer patients in the RxPONDER clinical trial.
Key Design and Genomic Analysis of the RxPONDER Phase 3 Trial
The RxPONDER (NCT01272037) Phase 3 trial, led by the National Cancer Institute (NCI) and SWOG Cancer Research Group, was designed for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer patients with 1-3 positive lymph nodes. This trial compared the efficacy of standard endocrine therapy alone versus endocrine therapy plus chemotherapy in patients with an Oncotype DX Breast Recurrence Score of 25 or less, using Exact Sciences' (EXAS) 21-gene-based breast cancer recurrence prediction test. This aimed to provide a turning point in reducing unnecessary chemotherapy toxicity and realizing personalized precision medicine for patients.
Significant Differences in Clinical Efficacy Based on Menopausal Status
The results of the clinical trial revealed significant differences in the additional benefit of chemotherapy based on the patient's menopausal status. In postmenopausal patients, the addition of chemotherapy showed no clinical benefit, with a hazard ratio (HR) of 1.02 (95% confidence interval 0.82-1.26, p=0.89) for 5-year invasive disease-free survival (IDFS). In contrast, in premenopausal patients, the addition of chemotherapy reduced the risk of cancer recurrence by approximately 40%, with an IDFS HR of 0.60 (95% confidence interval 0.43-0.83, p=0.002).
Guideline Changes Leading to Treatment Reduction and Market Impact
These clinical results have directly led to revisions in global standard treatment guidelines, including the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). Even in lymph node-positive postmenopausal patients, those with low recurrence scores can safely omit highly toxic chemotherapy, significantly improving patients' quality of life. This also has economic benefits by significantly reducing unnecessary chemotherapy prescriptions and associated adverse event treatment costs.
Changes in the Genomic Diagnostics Market and Strengthening of EXAS's Dominance
The global breast cancer diagnostics market is projected to grow from approximately $5.9 billion in 2025 to 7-9% annually. Exact Sciences (EXAS) has further solidified its dominant position with Oncotype DX. While competitors such as Agendia's MammaPrint and Myriad Genetics' EndoPredict are pursuing the market, Oncotype DX is the only diagnostic test that has confirmed the possibility of omitting chemotherapy in lymph node-positive patients through a randomized Phase 3 clinical trial. This clinical success will significantly expand the scope of insurance coverage, serving as a key driver for the long-term growth of Exact Sciences' precision medicine business.
The success of the RxPONDER Phase 3 trial will solidify Exact Sciences' (EXAS) dominant position in the approximately $5.9 billion global breast cancer diagnostics market, leading to a significant increase in related revenue and insurance claims in the short term. In the long term, as the trend of chemotherapy de-escalation becomes established, it will lead to a decrease in demand for traditional chemotherapy drugs such as taxanes, while increasing the long-term prescription rate of hormone receptor-targeted therapies such as tamoxifen and aromatase inhibitors. While Agendia and Myriad Genetics are promoting alternative diagnostic platforms, it will be difficult for them to overcome the entry barrier of Oncotype DX, which has secured a standard of care status based on large-scale, prospective Phase 3 clinical data. This study will serve as an opportunity for new drug developers to refine biomarker selection criteria in the breast cancer clinical trial design phase by enforcing genomic-based precision medicine design based on menopausal status.
Source: ClinicalTrials.gov (api_ct)